{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:39:51Z","timestamp":1789673991616,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,12,23]],"date-time":"2013-12-23T00:00:00Z","timestamp":1387756800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,12,23]],"date-time":"2013-12-23T00:00:00Z","timestamp":1387756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1038\/pr.2013.246","type":"journal-article","created":{"date-parts":[[2013,12,23]],"date-time":"2013-12-23T16:53:02Z","timestamp":1387817582000},"page":"527-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies"],"prefix":"10.1038","volume":"75","author":[{"given":"Gordian L.","family":"Schmid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"K\u00e4ssner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holm H.","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"K\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Kratzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"H\u00e4ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred-P.","family":"Zepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kowalzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Laner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Starke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska K.","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Viehweger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wieland","family":"Kiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Garten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,23]]},"reference":[{"key":"BFpr2013246_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/humu.10257","volume":"22","author":"C Eng","year":"2003","unstructured":"Eng C . PTEN: one gene, many syndromes. Hum Mutat 2003;22:183\u201398.","journal-title":"Hum Mutat"},{"key":"BFpr2013246_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/sj.ejhg.5200289","volume":"7","author":"MR Nelen","year":"1999","unstructured":"Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999;7:267\u201373.","journal-title":"Eur J Hum Genet"},{"key":"BFpr2013246_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","volume":"18","author":"MH Tan","year":"2012","unstructured":"Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C . Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18:400\u20137.","journal-title":"Clin Cancer Res"},{"key":"BFpr2013246_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/jmedgenet-2012-101339","volume":"50","author":"V Bubien","year":"2013","unstructured":"Bubien V, Bonnet F, Brouste V, et al.; French Cowden Disease Network. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013;50:255\u201363.","journal-title":"J Med Genet"},{"key":"BFpr2013246_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncponc1112","volume":"5","author":"DJ Marsh","year":"2008","unstructured":"Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 2008;5:357\u201361.","journal-title":"Nat Clin Pract Oncol"},{"key":"BFpr2013246_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/pbc.23098","volume":"57","author":"I Iacobas","year":"2011","unstructured":"Iacobas I, Burrows PE, Adams DM, Sutton VR, Hollier LH, Chintagumpala MM . Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer 2011;57:321\u20133.","journal-title":"Pediatr Blood Cancer"},{"key":"BFpr2013246_CR7","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1053\/j.gastro.2012.01.011","volume":"142","author":"M Heindl","year":"2012","unstructured":"Heindl M, H\u00e4ndel N, Ngeow J, et al. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenterology 2012;142:1093\u20131096.e6.","journal-title":"Gastroenterology"},{"key":"BFpr2013246_CR8","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1210\/en.2004-0777","volume":"146","author":"F Tremblay","year":"2005","unstructured":"Tremblay F, Gagnon A, Veilleux A, Sorisky A, Marette A . Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 2005;146:1328\u201337.","journal-title":"Endocrinology"},{"key":"BFpr2013246_CR9","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.1158\/0008-5472.CAN-09-0299","volume":"69","author":"K Yu","year":"2009","unstructured":"Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009;69:6232\u201340.","journal-title":"Cancer Res"},{"key":"BFpr2013246_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1042\/BJ20090489","volume":"421","author":"JM Garc\u00eda-Mart\u00ednez","year":"2009","unstructured":"Garc\u00eda-Mart\u00ednez JM, Moran J, Clarke RG, et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 2009;421:29\u201342.","journal-title":"Biochem J"},{"key":"BFpr2013246_CR11","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","volume":"7","author":"SM Maira","year":"2008","unstructured":"Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851\u201363.","journal-title":"Mol Cancer Ther"},{"key":"BFpr2013246_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/ejhg.2008.162","volume":"16","author":"GM Blumenthal","year":"2008","unstructured":"Blumenthal GM, Dennis PA . PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008;16:1289\u2013300.","journal-title":"Eur J Hum Genet"},{"key":"BFpr2013246_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.critrevonc.2007.06.002","volume":"63","author":"J Lopiccolo","year":"2007","unstructured":"Lopiccolo J, Ballas MS, Dennis PA . PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. Crit Rev Oncol Hematol 2007;63:203\u201314.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFpr2013246_CR14","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500\u20138.","journal-title":"Cancer Res"},{"key":"BFpr2013246_CR15","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065\u201374.","journal-title":"J Clin Invest"},{"key":"BFpr2013246_CR16","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.1073\/pnas.0609139104","volume":"104","author":"R Mehrian-Shai","year":"2007","unstructured":"Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K\/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 2007;104:5563\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFpr2013246_CR17","first-page":"3373","volume":"61","author":"S Huang","year":"2001","unstructured":"Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ . p53\/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res 2001;61:3373\u201381.","journal-title":"Cancer Res"},{"key":"BFpr2013246_CR18","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.4161\/cc.10.22.18124","volume":"10","author":"P Yellen","year":"2011","unstructured":"Yellen P, Saqcena M, Salloum D, et al. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011;10:3948\u201356.","journal-title":"Cell Cycle"},{"key":"BFpr2013246_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","volume":"22","author":"DD Sarbassov","year":"2006","unstructured":"Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB. Mol Cell 2006;22:159\u201368.","journal-title":"Mol Cell"},{"key":"BFpr2013246_CR20","doi-asserted-by":"publisher","first-page":"11285","DOI":"10.1073\/pnas.1934283100","volume":"100","author":"H Matsuzaki","year":"2003","unstructured":"Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A . Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci USA 2003;100:11285\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFpr2013246_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1517\/17425255.2012.681376","volume":"8","author":"PG Richardson","year":"2012","unstructured":"Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC . Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol 2012;8:623\u201333.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"BFpr2013246_CR22","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1002\/cncr.27668","volume":"118","author":"DC Cho","year":"2012","unstructured":"Cho DC, Hutson TE, Samlowski W, et al. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer 2012;118:6055\u201362.","journal-title":"Cancer"},{"key":"BFpr2013246_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10278-004-1014-6","volume":"17","author":"A Rosset","year":"2004","unstructured":"Rosset A, Spadola L, Ratib O . OsiriX: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging 2004;17:205\u201316.","journal-title":"J Digit Imaging"},{"key":"BFpr2013246_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/sj.ijo.0801520","volume":"25","author":"M Wabitsch","year":"2001","unstructured":"Wabitsch M, Brenner RE, Melzner I, et al. Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation. Int J Obes Relat Metab Disord 2001;25:8\u201315.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BFpr2013246_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/1535-7163.MCT-10-0905","volume":"10","author":"E Vilar","year":"2011","unstructured":"Vilar E, Perez-Garcia J, Tabernero J . Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011;10:395\u2013403.","journal-title":"Mol Cancer Ther"},{"key":"BFpr2013246_CR26","unstructured":"Memorial Sloan-Kettering Cancer Center, Novartis. A Phase 1b\/2 Study of BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC), 2013. (\n                    http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01453595\n                    \n                  )."},{"key":"BFpr2013246_CR27","unstructured":"Aeterna Zentaris, Sarah Cannon Research Institute. A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients with Refractory Advanced Colorectal Cancer, 2013. (\n                    http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01097018\n                    \n                  )."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/pr2013246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/pr2013246","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/pr2013246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:59:34Z","timestamp":1684472374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pr2013246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,23]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["BFpr2013246"],"URL":"https:\/\/doi.org\/10.1038\/pr.2013.246","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,23]]},"assertion":[{"value":"25 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}